A Phase 3 interventional study of Sirolimus (Rapamune) and Cyclosporine or Tacrolimus in Liver Transplantation, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Terminated at 42 sites in 12 countries. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2010-04-28.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the sirolimus conversion regimen as compared with the calcineurin inhibitor continuation regimen with regards to renal function in stable liver transplant subjects.
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
First submitted before Wyeth became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Sirolimus (Rapamune)
Drug: Cyclosporine or Tacrolimus
Drug pages: Cyclosporine · Tacrolimus
Change From Baseline Adjusted Mean in Glomerular Filtration Rate (GFR)
GFR is an index of kidney function. GFR was calculated using Cockcroft-Gault method. A normal GFR is \>90 mL/min, higher values indicate better function. Change=adjusted mean of 12 months minus baseline. Mean adjusted for baseline GFR, with antimetabolite therapy status and hepatitis C status as fixed effects.
Time frame: Baseline and 12 months
Patient and Graft Survival
Endpoint was a composite assessment of patient and graft survival. Patients categorized as graft survival or graft loss. Graft loss defined as pure graft loss (requiring retransplant) or death (with a functioning graft), if the event occurred in the first 12 months after randomization. Patients with missing graft data were counted as graft losses.
Time frame: 12 months
Number of Patients With a Biopsy Confirmed Acute Rejection
Overall event rate is determined as yes or no.
Time frame: 12 months
Mean Serum Creatinine
Observed mean values for serum creatinine.
Time frame: 12 months
Patients were recruited October 2002 to November 2006.
| Milestone | Sirolimus (SRL) Conversion | Calcineurin Inhibitors (CNI) Continuation |
|---|---|---|
| Started | 393 | 214 |
| Completed | 389 | 210 |
| Not completed | 4 | 4 |
| Withdrew: Did not receive test article | 4 | 4 |
| Milestone | Sirolimus (SRL) Conversion | Calcineurin Inhibitors (CNI) Continuation |
|---|---|---|
| Started | 389 | 210 |
| Completed | 249 | 187 |
| Not completed | 140 | 23 |
| Withdrew: Adverse event | 94 | 11 |
| Withdrew: Lost to follow-up | 1 | 3 |
| Withdrew: Nonmedical event | 7 | 3 |
| Withdrew: Withdrawal by subject | 16 | 3 |
| Withdrew: Protocol violation | 11 | 3 |
| Withdrew: Lack of efficacy | 11 | 0 |
GFR is an index of kidney function. GFR was calculated using Cockcroft-Gault method. A normal GFR is \>90 mL/min, higher values indicate better function. Change=adjusted mean of 12 months minus baseline. Mean adjusted for baseline GFR, with antimetabolite therapy status and hepatitis C status as fixed effects.
| mL/min | Sirolimus (SRL) Conversion | Calcineurin Inhibitors (CNI) Continuation |
|---|---|---|
| Change From Baseline Adjusted Mean in Glomerular Filtration Rate (GFR) | -4.45 ± 1.12 | -3.07 ± 1.36 |
Overall event rate is determined as yes or no.
| patients | Sirolimus (SRL) Conversion | Calcineurin Inhibitors (CNI) Continuation |
|---|---|---|
| Yes | 46 | 13 |
| No | 347 | 201 |
Observed mean values for serum creatinine.
| µmol/L | Sirolimus (SRL) Conversion | Calcineurin Inhibitors (CNI) Continuation |
|---|---|---|
| Mean Serum Creatinine | 119.0 ± 38.9 | 122.4 ± 31.5 |
Endpoint was a composite assessment of patient and graft survival. Patients categorized as graft survival or graft loss. Graft loss defined as pure graft loss (requiring retransplant) or death (with a functioning graft), if the event occurred in the first 12 months after randomization. Patients with missing graft data were counted as graft losses.
| patients | Sirolimus (SRL) Conversion | Calcineurin Inhibitors (CNI) Continuation |
|---|---|---|
| Graft survival | 367 | 202 |
| Graft loss (total) | 26 | 12 |
| Graft loss: Pure (with retransplant) | 0 | 0 |
| Graft loss: Death | 13 | 3 |
| Graft loss: Incomplete data | 13 | 9 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sirolimus (SRL) Conversion | — | — | 386/389 (99.2%) |
| Calcineurin Inhibitors (CNI) Continuation | — | — | 201/210 (95.7%) |
| Event | Sirolimus (SRL) Conversion | Calcineurin Inhibitors (CNI) Continuation |
|---|---|---|
| Skin carcinomaSkin and subcutaneous tissue disorders | 14/389 | 19/210 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 17/389 | 4/210 |
| FeverGeneral disorders | 16/389 | 8/210 |
| DiarrheaGastrointestinal disorders | 16/389 | 5/210 |
| Liver function tests abnormalGastrointestinal disorders | 15/389 | 3/210 |
| Local reaction to procedureGeneral disorders | 13/389 | 3/210 |
| AnemiaBlood and lymphatic system disorders | 12/389 | 4/210 |
| Cerebrovascular accidentVascular disorders | 1/389 | 6/210 |
| HerniaGeneral disorders | 11/389 | 3/210 |
| Abdominal painGeneral disorders | 10/389 | 4/210 |
| Event | Sirolimus (SRL) Conversion | Calcineurin Inhibitors (CNI) Continuation |
|---|---|---|
| HyperlipemiaMetabolism and nutrition disorders | 159/389 | 20/210 |
| DiarrheaGastrointestinal disorders | 136/389 | 38/210 |
| Peripheral edemaMetabolism and nutrition disorders | 127/389 | 29/210 |
| RashSkin and subcutaneous tissue disorders | 111/389 | 16/210 |
| HypercholesteremiaMetabolism and nutrition disorders | 110/389 | 9/210 |
| StomatitisGastrointestinal disorders | 103/389 | 4/210 |
| InfectionGeneral disorders | 97/389 | 43/210 |
| AnemiaBlood and lymphatic system disorders | 94/389 | 19/210 |
| HeadacheGeneral disorders | 84/389 | 23/210 |
| AstheniaGeneral disorders | 79/389 | 28/210 |
| Age Continuous(years) | Sirolimus (SRL) Conversion | Calcineurin Inhibitors (CNI) Continuation | Total |
|---|---|---|---|
| Median | 57.0 (23.0 to 76.0) | 56.5 (21.0 to 73.0) | 57.0 (21.0 to 76.0) |
| Sex: Female, Male(Participants) | Sirolimus (SRL) Conversion | Calcineurin Inhibitors (CNI) Continuation | Total |
|---|---|---|---|
| Female | 122 | 64 | 186.0 |
| Male | 271 | 150 | 421.0 |
| Mean serum creatinine levels(μmol/L) | Sirolimus (SRL) Conversion | Calcineurin Inhibitors (CNI) Continuation | Total |
|---|---|---|---|
| Mean | 122.9 ± 32.3 | 125.2 ± 31.9 | 123.7 ± 32.2 |
The record gives a start of Dec 2002, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sirolimus · Cyclosporine · Tacrolimus
Wyeth is now a wholly owned subsidiary of Pfizer →